Tegafur, Gimeracil, and Oteracil Potassium Capsules 20mg (TS-1® / ティーエスワン配合カプセルT20)

JPY ¥18,300

Japanese antimetabolite (Tegafur, Gimeracil, and Oteracil Potassium 20mg). Oral capsule for treatment of gastric, colorectal, head and neck, non-small cell lung, breast, pancreatic, and biliary tract cancers. 56 capsules (14 capsules x 4) per pack. Mfd. by Taiho Pharmaceutical Co., Ltd., Japan.

Bulk deal
Quantity Discount Discounted price
5 - 9 8% JPY ¥16,836
10 - 19 12% JPY ¥16,104
20 + 18% JPY ¥15,006
SKU: TS1-20-CAP Category:

Description

Product Overview / 商品概要

TS-1 Combination Capsules T20 (ティーエスワン配合カプセルT20)
Generic: Tegafur, Gimeracil, and Oteracil Potassium / テガフール・ギメラシル・オテラシルカリウム
Therapeutic Category: Antimetabolite / 代謝拮抗剤
Manufactured by: Taiho Pharmaceutical Co., Ltd. / 大鵬薬品工業株式会社

Composition & Specification / 組成・規格

Active Ingredient: Tegafur 20mg, Gimeracil 5.8mg, Oteracil Potassium 19.6mg per capsule / 1カプセル中 テガフール 20mg、ギメラシル 5.8mg、オテラシルカリウム 19.6mg
Additives: Lactose hydrate, Magnesium stearate, Gelatin, Sodium lauryl sulfate, Titanium dioxide / 乳糖水和物、ステアリン酸マグネシウム、ゼラチン、ラウリル硫酸ナトリウム、酸化チタン
Appearance: White opaque hard capsule containing white powder and granules. Size 4 capsule. Overall length 14.5mm, major axis 5.2mm, minor axis 5.0mm, weight approx. 179mg. Identification code: TC442
外観: 白色の粉末及び粒を含む白色の不透明硬カプセル剤である。4号カプセル。全長14.5mm、長径5.2mm、短径5.0mm、質量約179mg。識別コード: TC442

Indications / 効能効果

EN: Gastric cancer, colorectal cancer, head and neck cancer, non-small cell lung cancer, inoperable or recurrent breast cancer, pancreatic cancer, biliary tract cancer, postoperative drug therapy for hormone receptor-positive and HER2-negative breast cancer with high risk of recurrence
JA: 胃癌、結腸・直腸癌、頭頸部癌、非小細胞肺癌、手術不能又は再発乳癌、膵癌、胆道癌、ホルモン受容体陽性かつHER2陰性で再発高リスクの乳癌における術後薬物療法

Dosage and Administration / 用法用量

EN: Method A: Administer orally twice daily (after breakfast and after dinner) for 28 consecutive days, followed by a 14-day rest period, repeated as one course. Body surface area <1.25m2: 40mg/dose; 1.25m2 to <1.5m2: 50mg/dose; ≥1.5m2: 60mg/dose. Method B: 21 days on, 14 days off. Method C: 14 days on, 7 days off. Method D: 14 days on, 14 days off. Method E: 7 days on, 7 days off. Method F: BSA <1.25m2: morning 40mg, evening 20mg; 1.25m2 to <1.5m2: 40mg/dose; ≥1.5m2: 50mg/dose; 14 days on, 7 days off. In combination with endocrine therapy, administer orally twice daily (after breakfast and after dinner) for 14 consecutive days, followed by a 7-day rest period, repeated as one course for up to 1 year. BSA <1.25m2: 40mg/dose; 1.25m2 to <1.5m2: 50mg/dose; ≥1.5m2: 60mg/dose.
JA: 〈胃癌、結腸・直腸癌、頭頸部癌、非小細胞肺癌、手術不能又は再発乳癌、膵癌、胆道癌〉A法:通常、成人には初回投与量(1回量)を体表面積に合わせて基準量とし、朝食後及び夕食後の1日2回、28日間連日経口投与し、その後14日間休薬する。これを1コースとして投与を繰り返す。体表面積1.25m2未満:40mg/回、1.25m2以上1.5m2未満:50mg/回、1.5m2以上:60mg/回。B法:21日間連日投与後14日間休薬。C法:14日間連日投与後7日間休薬。D法:14日間連日投与後14日間休薬。E法:7日間連日投与後7日間休薬。F法:体表面積1.25m2未満:朝40mg/回、夕20mg/回、1.25m2以上1.5m2未満:40mg/回、1.5m2以上:50mg/回、14日間連日投与後7日間休薬。〈ホルモン受容体陽性かつHER2陰性で再発高リスクの乳癌における術後薬物療法〉内分泌療法剤との併用において、通常、成人には次の投与量を朝食後及び夕食後の1日2回、14日間連日経口投与し、その後7日間休薬する。これを1コースとして最長1年間、投与を繰り返す。体表面積1.25m2未満:40mg/回、1.25m2以上1.5m2未満:50mg/回、1.5m2以上:60mg/回。

Contraindications / 禁忌

EN: Patients with a history of serious hypersensitivity to any component of this product; patients with serious bone marrow suppression; patients with serious renal impairment; patients with serious hepatic impairment; patients receiving other fluoropyrimidine antineoplastic agents (including combination therapies); patients receiving flucytosine; pregnant women or women who may be pregnant
JA: 本剤の成分に対し重篤な過敏症の既往歴のある患者、重篤な骨髄抑制のある患者、重篤な腎障害のある患者、重篤な肝障害のある患者、他のフッ化ピリミジン系抗悪性腫瘍剤(これらの薬剤との併用療法を含む)を投与中の患者、フルシトシンを投与中の患者、妊婦又は妊娠している可能性のある女性

Regulatory Information / 規制情報

Approval No.: 22100AMX00886000
Sales Started: March 1999 / 1999年3月
Classification Code: 874229
Storage: Store at room temperature / 室温保存
Shelf Life: 36 months / 36ヶ月

Packaging / 包装

Main Package (for sale): 56 capsules (14 capsules x 4) / 56カプセル(14カプセル×4)
Other Available Packages (by special order): PTP blister pack: 56 capsules (14 capsules x 4), 84 capsules (14 capsules x 6), 140 capsules (14 capsules x 10)

Full product insert (添付文書) is attached as a downloadable PDF. For detailed precautions, drug interactions, and safety information, please refer to the official package insert.

Additional information

重さ 0.15 kg

Reviews

There are no reviews yet.

Be the first to review “Tegafur, Gimeracil, and Oteracil Potassium Capsules 20mg (TS-1® / ティーエスワン配合カプセルT20)”

メールアドレスが公開されることはありません。 ※ が付いている欄は必須項目です

Export from Japan — Tegafur, Gimeracil, and Oteracil Potassium Capsules 20mg (TS-1®

🏭 Supply & Origin

  • Country of Origin: Japan
  • Regulatory Standard: PMDA (Japan) / GMP Compliant
  • Pharmacopoeia: Japanese Pharmacopoeia (JP)
  • Supplier: Mate Co., Ltd. — Licensed Pharmaceutical Wholesaler (License No. B14309, Osaka)
  • Supply Capacity: Full-line sourcing through Japan's regulated distribution channels

🚚 Shipping & Trade Terms

  • Incoterms: FOB Kansai International Airport (KIX)
  • Shipping: Air freight via B/L or AWB
  • Payment: 100% T/T in advance
  • Lead Time: 2-4 weeks after payment confirmation
  • Available Regions: EU, LATAM, APAC, Middle East, Africa

Request a Quotation

For pricing, MOQ, and regulatory documentation, contact our export team:

Email: kurimoto@mate-osaka.co.jp
Tel: +81-72-665-5736

All exports are conducted through proper regulatory procedures including customs clearance, B/L or AWB documentation, and T/T advance payment. We do not engage in hand-carry, cash transactions, or sales to unlicensed parties.